NAMSW NewAmsterdam Pharma Company N.V
$10.75▲ +0.00%
Healthcare
Other
Volume 322
Avg Volume (10D) 670
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
8.25 - 30.45
% vs 50 MA
-34.99%
% vs 200 MA
-57.17%
RSI-14
27.6
MACD Histogram
-0.0700
Beta (1Y vs SPY)
0.81
Free Cash Flow
-$39.29M
Gross Rev
$3.70M
Gross Profit
$3.70M
EBITDA
-$59.72M
COGS
–
Operating Exp
$68.57M
Operating Income
-$64.86M
EBIT
-$64.86M
Pretax Income
-$64.14M
Net Income
-$64.14M
Price & Volume History
Loading chart…
Recent News
Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?
Simply Wall St. · Oct 13, 2026 7:22 PM ET
NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says
MT Newswires · Oct 5, 2026 11:34 AM ET
RBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative Risk
MT Newswires · Oct 5, 2026 6:59 AM ET
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 4:01 PM ET
NewAmsterdam Pharma Doses First Participant in Phase 2b Trial for Preclinical Alzheimer's Disease
MT Newswires · Sep 29, 2026 10:23 AM ET
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
GlobeNewswire · Sep 29, 2026 8:00 AM ET
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
Insider Monkey · Sep 22, 2026 9:20 PM ET
NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco
MT Newswires · Sep 21, 2026 10:09 AM ET
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
GlobeNewswire · Sep 21, 2026 9:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See NAMSW's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.